BIONANO GENOMICS ($BNGO) posted quarterly earnings results for Q1 2026 on Wednesday, May 13th. The company reported earnings of -$0.76 per share, beating estimates of -$0.97 by $0.21. The company also reported revenue of $6,690,000, missing estimates of $6,698,850 by $-8,850.
Stock price change since market close: -2.15%
You can see Quiver Quantitative's $BNGO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIONANO GENOMICS Hedge Fund Activity
We have seen 14 institutional investors add shares of BIONANO GENOMICS stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GSA CAPITAL PARTNERS LLP added 337,777 shares (+inf%) to their portfolio in Q4 2025, for an estimated $516,798
- DRW SECURITIES, LLC removed 168,453 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $197,090
- TWO SIGMA INVESTMENTS, LP added 40,513 shares (+inf%) to their portfolio in Q4 2025, for an estimated $61,984
- GEODE CAPITAL MANAGEMENT, LLC added 39,928 shares (+148.8%) to their portfolio in Q4 2025, for an estimated $61,089
- RENAISSANCE TECHNOLOGIES LLC added 37,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $56,610
- VANGUARD GROUP INC added 31,848 shares (+63.1%) to their portfolio in Q4 2025, for an estimated $48,727
- PRUDENTIAL FINANCIAL INC added 28,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $32,759
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BIONANO GENOMICS Government Contracts
We have seen $67,239 of award payments to $BNGO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROCUREMENT OF REAGENTS FOR OPTICAL GENOME MAPPING EXPERIMENTS: $25,624
- BIONANOGENOMICS INC:1186637 [25-006792]: $24,115
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
BIONANO GENOMICS Analyst Ratings
Wall Street analysts have issued reports on $BNGO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
To track analyst ratings and price targets for BIONANO GENOMICS, check out Quiver Quantitative's $BNGO forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
